| INTRODUCTION
Oral dysesthesia (OD), also known as burning mouth syndrome (BMS), is a chronic orofacial pain condition that is associated with moderate-to-intense pain of a burning or similar nature, which affects the oral mucosa. 1, 2 Patients affected by this condition may suffer disruption to normal social relationships and a general diminution in quality of life. 3, 4 The International Association for the Study of Pain, International Headache Society and other recent literature have provided classification and diagnostic criteria for BMS that may be applied in both clinical and research settings (Table 1) . [5] [6] [7] [8] Burning mouth syndrome typically affects women more frequently than men at a female to male ratio of approximately 3:1. 2 The majority of affected individuals are over 50 years of age and the postmenopausal period of life is frequently implicated. 9, 10 The prevalence of BMS is estimated to be between 0.7% and 4.5% based on different sample populations and inclusion criteria. [9] [10] [11] [12] [13] The lack of strict protocols for clinical and serological examination of patients to differentiate between BMS and other diseases associated with painful intra-oral mucosal symptoms continues to hinder a sound epidemiological understanding of BMS being established from existing research.
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The etiopathogenesis of OD principally reflects psychological factors, and a number of systemic (eg, diabetes mellitus) and local factors have all been suggested to be related to symptoms. 2 Infection by Candida albicans continues to be quoted as a possible cause but there are no consistent supportive data. [14] [15] [16] [17] As Candida is a commensal, it might be expected to frequently give rise to oral mucosal discomfort in patients at risk of candidal overgrowth, but not other conditions.
Reports of Candida oral carriage rates among BMS patients range from 25% to 93.7% within the published literature. Candida species (Table 3) .
Statistical analysis of the frequency of Candida carriage among the subgroups showed no significant differences (P < .05) with exception of the subgroups of patients diagnosed with xerostomia, Candida-associated denture-induced stomatitis, and candidosis/angular cheilitis. The oral load of Candida species was significantly higher in these 3 groups relative to BMS patients. Statistical analysis of the Candida counts among the subgroups showed no significant differences (P < .05) with the exception of the subgroups of patients diagnosed with xerostomia, denture-induced stomatitis, and candidosis/angular cheilitis. The oral load of Candida species was significantly higher in these 3 groups when compared with the BMS patient group (Table 3) .
| Candida load

| DISCUSSION
The results of this paper support the hypothesis that there is no association between the presence or load of Candida and the diagnosis of burning mouth syndrome/oral dysesthesia. This assertion is made on the basis that Candida carriage was not found to be significantly higher among patients with BMS than the other oral diseases assessed.
T A B L E 3 Candida counts and prevalence compared between burning mouth syndrome and other groups The frequency of carriage of Candida species in the present group of patients was 63.3%. Previous studies have reported that 25%-93.7% of patients with BMS may carry Candida [14] [15] [16] [18] [19] [20] [21] [22] [23] ; however, it is critical to note that most show that the frequency of carriage among BMS patients is not significantly greater than in control groups. 18, 19, 23 Indeed, 70% or more of healthy patients may harbor
Candida species in the mouth. 24 Burning mouth syndrome patients within this study did not exhibit a significantly higher prevalence or load of Candida than any other oral disease examined. The oral carriage of Candida among patients with BMS was in fact found to be significantly lower than in patients diagnosed with xerostomia, Candida-associated dentureinduced stomatitis and candidosis/angular cheilitis. The significantly higher carriage of Candida species observed in patients with clinical signs of Candida infection (denture-induced stomatitis, candidosis/ angular cheilitis) or local predisposing factors for increased Candida carriage (xerostomia) would be anticipated. 18 This finding may be a reassuring indication that the absence of association between Candida carriage and BMS demonstrated within the data presented is likely to be genuine. Further evidence of consistency is suggested by the general similarity in P-value among corresponding conditions when examining Candida count and prevalence using separate statistical analyses.
An interesting finding within this study is a very high mean level of Candida among patients with atypical facial pain. The authors do not believe that this is an indicative finding since high outliers in this group skewed the data. Indeed, the median is considered more representative of the general distribution of load and was therefore used in tests for significant differences in Candida prevalence among different disease states.
As no detailed Candida typing was undertaken as part of this study, it is possible that some of the supposed C. albicans isolates may have been C. dubliniensis. It is likely, however, that C. albicans was the most common type of Candida present, as previous studies of generally well individuals and those with BMS have consistently found C. albicans to be the dominant oral yeast. 15, 17, 19, 21, 24 The lack of a healthy control group for comparison within this study is a weakness that may be counteracted by a strong body of existing research that refutes the presence of a significant difference between Candida carriage among BMS vs control patients. 18, 19, 23 The data presented confirms previous findings that the existence of xerostomia is associated with increased Candida presence. 18, 21 Since no previous research has compared Candida carriage among BMS patients with a wide range of alternative oral diseases, this unique perspective lends significant weight to the growing body of evidence that discredits a microbiological link between Candida infection and BMS.
Such a conclusion also yields important implications for the pharmaceutical management of BMS. Topical clonazepam therapy is currently the only effective pharmaceutical intervention for BMS that is based on a randomized controlled trial 6, 25 and is well supported by other studies. 26, 27 There is currently no sound research to support the use of antifungal medication in the management of correctly diagnosed BMS. 6, 20 The findings of this study provide further evidence against a microbiological rationale for such an approach.
A secondary application of these findings may arise through assessment of the diagnostic potential for Candida testing to distinguish between different presenting oral diseases. The present results indicate that Candida testing may be useful to distinguish between BMS and frank oral candidosis or a predisposing oral environment of xerostomia. However, the clinician must balance the information to be gained from this diagnostic procedure against considerations of costs, risks and delays in treatment that such a test may potentiate.
Considering the differentiation potential that a simple clinical history, examination and in-chair saliva test may yield, a further probe to measure Candida carriage in such circumstances may be diagnostically superfluous, despite its potential.
The present results strongly support the notion that Candida is 
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